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Antibody responses have not been fully characterised in chronically HIV/HCV patients receiving 
antiretroviral therapy (ART). Seventeen HIV/HCV patients receiving ART were followed for a 
median (range) interval of 597 (186-766) weeks. Prior to ART, HIV/HCV patients had lower 
levels of antibodies reactive with HCV core and JFH-1, and lower genotype cross-reactive 
neutralising antibodies (nAb) titres than HCV patients. Levels of JFH-1 reactive antibody 
increased on ART, irrespective of CD4+ T-cell counts or changes in serum ALT levels. The 
appearance of nAb coincided with control of HCV viral replication in five HIV/HCV patients. In 
other patients, HCV viral loads remained elevated despite nAb responses. Sustained virological 
responses following HCV therapy were associated with reduced antibody responses to JFH-1 and 
core but elevated responses to non-structural proteins. We conclude that nAb responses alone 
may fail to clear HCV, but contribute to control of viral replication in some HIV/HCV patients 











Co-infection with hepatitis C virus (HCV) is common in human immunodeficiency virus (HIV)-
infected patients as the viruses share routes of transmission. Co-infected patients have higher 
HCV loads and faster progression to liver disease. Antiretroviral therapy (ART) has improved 
life expectancy, so more cases of HCV-associated liver disease arise. Beneficial effects of ART 
may not be as great in co-infected patients [1, 2], but HCV-specific cell-mediated immune 
responses are restored [3, 4]. In some patients, this coincided with elevated serum alanine 
aminotransferase (ALT) levels [5-8] in a phenomenon known as immune restoration disease 
(IRD) [6, 8]. Longitudinal studies of antibody responses in HIV/HCV patients receiving ART are 
limited. In a three year study, HIV/HCV patients were unable to normalise circulating B-cell 
counts or serum total IgG levels [9]. Titres of HCV-reactive antibodies increased after 1 year of 
ART, with no changes in HCV viral loads [10].  
 
The establishment of a cell-culture system for HCV has allowed evaluation of antibodies that can 
neutralise HCV infection. Neutralising antibody (nAb) can be detected using the HCV genotype 
2a strain, JFH-1, in HCV mono-infected patients chronically infected with different HCV 
genotype [11, 12]. HIV co-infection reduced nAb levels in a cross-sectional study [13], but we 
have found no longitudinal data examining HIV/HCV patients after starting ART. We present an 
extended analysis of HCV antibody responses detected using JFH-1, and recombinant core and 
non-structural antigens. Changes observed on ART are analysed in individual patients to dissect 
out causes and consequences of perturbations in the HCV viral loads and CD4+ T-cell counts. 
 
2. Materials and Methods 




HIV/HCV patients (n=17) attending Outpatient Clinics at Royal Perth Hospital (Western 
Australia) were monitored for a median (range) interval of 597 (186-766) weeks after starting 
ART (triple therapy with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor). 
Some patients had participated in previous studies [6, 8]. Initial diagnoses were based on 
serology and confirmed by COBAS AMPLICOR HCV Test (Roche Diagnostics). Four 
patients also received anti-HCV therapy during the follow-up period. We included seventeen 
HCV mono-infected patients attending Royal Perth Hospital, matched for sex and HCV 
genotype to co-infected patients. HCV mono-infected patients were negative for hepatitis B 
surface antigens and antibodies to HIV, and had not been treated with IFNα/ribavirin. Seventeen 
healthy individuals with no reported exposure to HCV or HIV were included as controls. All 
subjects gave their informed consent and the study was approved by the Human Ethics 
Committee of Royal Perth Hospital.  
 
2.2 Biochemical markers, CD4+ and CD8+ T-cell counts and HIV RNA levels  
Serum ALT levels were measured on an automated analyser (Hitachi 917: Roche Diagnostics). 
CD4+ and CD8+ T-cell counts were determined from fresh blood specimens by standard flow 
cytometric analyses. Plasma HIV RNA levels were determined by RT-PCR (Amplicor, Roche 
Diagnostics). Lower limits of the assay were 2.6 log10 copies/mL from 1996 to 1998 and 1.7 
log10 copies/mL from 1998.  
 
2.3 HCV RNA levels and HCV genotyping assay 
RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA). HCV RNA 
levels were quantitated using specific primers and Taqman probes for the conserved 5′UTR 




genotype was determined by RT-PCR with a melting curve analysis using FRET probes [16]. 
HCV mono-infected patients were genotyped using LiPA Kits (Inno-Lipa, Innogenetics, Ghent, 
Belgium). 
 
2.4 Total IgG and CMV antibody ELISAs  
Plates were coated overnight with 5µg/mL polyvalent goat antihuman immunoglobulin 
(Invitrogen), washed with 0.05% Tween/PBS and blocked with 5% BSA/PBS. Plates were 
washed again and plasma/serum serially diluted in 2% BSA/PBS was added.  Human IgG 
(0.5ug/mL, Sigma, Castle Hill, NSW, Australia) was diluted in 2% BSA/PBS as a standard. 
Bound Ig was detected with horseradish peroxidase conjugated anti-human IgG (Jackson 
Immunoresearch, West Grove, PA), followed by tetramethylbenzidine substrate (Sigma). 
Reactions were stopped with 1M H2SO4 and absorbance measured at 450nm. The coefficient of 
variance for the assay was 11%. 
 
To assess CMV-reactive antibody, plates were coated with a lysate of human foreskin fibroblasts 
infected with CMV AD169 as previously described [17]. The coefficient of variance was 13%.  
 
2.5 HCV antibody ELISAs  
Production of HCV (JFH-1) in human hepatoma HuH-7 cells has been previously described [18]. 
JFH-1 infected cells were resuspended in buffer containing protease inhibitors and subjected to 
decompression lysis. Lysates from the same number of uninfected HuH-7 cells were prepared as 
a negative control. Microtitre plates were coated with HuH-7 lysates, or 0.5µg/mL recombinant 
HCV core (genotype 1b), NS3 (genotype 1b), NS4 (genotype 1 a) or NS5 antigens 




Version 3.0 (Abbott, Chicago, IL) was assigned an arbitrary unit value as a standard. JFH-1 
antibody levels were determined by subtracting the value obtained with uninfected cells. 
Coefficients of variance were: 13% (JFH-1), 11% (HCV core), 6.3% (HCV NS3), 6.0% (HCV 
NS4) and 5.3% (HCV NS5).  
 
2.6 HCV Neutralisation Assay 
Viral supernatants harvested from JFH-1-infected cells were stored at -80C. Viral titer was 
ascertained by titrating supernatants and incubating on HuH-7 cells in a 96-well plate and 
counting the foci from duplicate wells to yield foci forming units/mL (FFU/mL). HCV 
neutralisation assay have been previously described [18]. HCV foci were counted using an AID 
ELISpot Reader v2.9 software (Autoimmun Diagnostika GmbH, Strassberg, Germany).  The 




Data are presented as median (range). Statistical analyses were performed using GraphPad Prism 
Version 5.01 (San Diego, CA). Differences between study groups were evaluated using the non-
parametric Mann-Whitney Tests. Correlations were assessed using Spearman’s Rank Correlation 
Coefficient. P-values<0.05 are considered statistically significant.  
 
3. Results 
3.1 Immunological, biochemical and virological profiles of patients during ART 
HIV/HCV patients (P1-17) are described in Table 1. HIV/HCV and HCV patients had similar 




HIV/HCV patients were significantly younger and had lower serum ALT levels and CD4+ T-cell 
counts than HCV mono-infected patients. Seven HIV/HCV patients (P1, P2, P7, P10, P11, P12, 
P17) started ART with CD4+ T-cell counts below 50 cells/L.  
 
Statistical analyses spanned 520 weeks, with most patients followed to this timepoint. Median 
(range) CD4+ T-cell counts increased from 150 (14–149) to 400 (200-1274) cells/L at 520 
weeks (Supplementary Figure 1a), with a significant increase at 104 weeks (p=0.05) and smaller 
increments thereafter. Eight patients (P1, P2, P7, P10, P11, P12, P15, P17) achieved more than 
a 4-fold increase in CD4+ T-cell counts. CD4+ T-cell counts remained below 200 cells/L in 
P17.  
 
Median serum ALT levels increased from 41 (15-86) to 81 (29-663) U/mL at week 52 (p=0.006) 
(Supplementary Figure 1b), and were elevated above baseline at 104 (p=0.07), 208 (p=0.01), 312 
(p=0.06) and 416 (p=0.006) weeks. Ten patients experienced a >3-fold rise in serum ALT to 
over 100 U/mL on ART (P1, P3, P4, P6, P9, P10, P11, P13, P16, P17). 
 
Persistent suppression of HIV replication (defined as less than one rebound in HIV viremia >3.0 
log10) on ART was achieved in P1, P2, P7, P8, P10, P12, P14 and P15. 
 
3.2 Low JFH-1 antibody responses did not reflect a global defect in antibody responses 
Levels of total IgG were higher in HIV/HCV patients prior to starting ART than HCV mono-
infected patients (p=0.0003) and controls (p=0.006) (Figure 1a). Amongst the individuals who 
were CMV seropositive (15 HIV/HCV patients, 10 HCV patients and 12 controls), CMV 




controls (p=0.003) (Figure 1b). CMV antibody levels were similar in mono-infected patients and 
controls.  
 
As this does not suggest a global defect in antibody responses, it is striking that HIV/HCV 
patients had lower levels of antibody reactive to JFH-1 and genotype cross-reactive nAb50 titres 
than HCV mono-infected patients (p<0.0001), although levels were higher than in controls 
(p<0.0001) (Figures 1c and 1h). P1, P5, P6, P9, P11, P12, P15, P16 and P17 had undetectable 
or low nAb50 titres.  HCV core antibody levels were also lower in HIV/HCV patients than HCV 
mono-infected patients (p=0.0002), but higher than controls (p<0.0001) (Figure 1d).  
 
In contrast, levels of antibody to NS3 and NS5 antigens were higher in HIV/HCV patients than 
HCV mono-infected patients (p<0.0001) (Figures 1e and 1g). NS4 antibody levels were similar 
in both patient groups (p=0.41) and higher than controls (p<0.0001) (Figure 1f). 
 
3.3 Levels of JFH-1 antibody are affected by CD4+ T-cell counts but not by HCV genotype 
CD4+ T-cell counts correlated weakly with JFH-1 reactive antibody levels in co-infected patients 
prior to starting ART (r=0.30, p=0.08), but not in HCV mono-infected patients (r=-0.19, p=0.49). 
A significant direct relationship was found between levels of antibody detected in the JFH-1 
ELISA and nAb50 titres in co-infected patients (r=0.61, p=0.009), with a weaker correlation in 
HCV mono-infected patients (r=0.39, p=0.12). Median (range) levels of JFH-1 reactive antibody 
for co-infected patients with HCV genotype 1, HCV genotype 2 and HCV genotype 3 were 
similar [12440 (0–430852), 79952 (9665–150238) and 14896 (472–251112), respectively]. 




genotype 2: 3700 (400-7000) and genotype 3: 1750 (0-5500); p=0.80]. nAb50 titres did not 
correlate with any immunological or biochemical parameters evaluated in both patient groups.  
 
3.4 Co-infected patients retained elevated levels of total IgG and antibody to CMV on ART 
Twelve of the 17 HIV/HCV patients had total IgG levels above mono-infected patients and 
controls in at least 1 follow-up sample (Figure 2a). For example, P2 began ART with high levels 
that normalised after 104 weeks, whilst P9 started with normal levels which rose and only 
normalised after 465 weeks. Only P14 retained low levels over 718 weeks of follow-up. CMV-
reactive antibody rose during the first year of ART and remained highest in co-infected patients 
(Figure 2b). However, P3 and P14 were CMV seronegative at baseline and did not seroconvert, 
and CMV antibody levels declined in P1, P2, P10 and P11.  
 
3.5 JFH-1 reactive antibody responses increased on ART, irrespective of baseline CD4+ T-
cell counts or changes in serum ALT levels during therapy 
With the exception of P11, JFH-1 reactive antibody levels increased in most patients within 52 
weeks on ART (Figure 2c) coincident with a rise in genotype cross-reactive nAb50 titres (Figure 
2d). For P1, P5 and P16, the rise in nAb50 titres was delayed (210, 257 and 91 weeks, 
respectively). After 205 (186-225) weeks, co-infected patients attained nAb50 titres similar to 
mono-infected patients, whereas levels of JFH-1 antibody remained lower than in mono-infected 
patients. HCV core antibody levels were significantly lower than mono-infected patients at 
baseline and during the first few years of ART, but normalised after 258 (242-270) weeks 
(Supplementary Figure 2a). HCV NS3 and NS5 antibody levels also began low and normalised 
after 522 (504-538) weeks (Supplementary Figures 2b & d), whereas NS4 antibody levels were 





When patients were stratified by CD4+ T-cell counts at recruitment, JFH-1 antibody responses 
were similar at equivalent timepoints (Supplementary Figures 3a & b). Interestingly, patients 
with <50 CD4+ T-cells/L at baseline developed nAb responses more rapidly than patients with 
>50 CD4+ T-cells/L (52 versus 260 weeks) (Supplementary Figure 3b). In contrast, JFH-1 
reactive antibody levels increased significantly by week 52 in both patient groups 
(Supplementary Figure 3a). There were no statistical differences in antibody responses between 
patients stratified by serum ALT levels (data not shown). 
 
3.6 JFH-1 antibody responses reflect HCV viral loads during ART  
Longitudinal samples identified three patterns associating JFH-1 antibody responses with HCV 
viral loads during ART. Informative examples are shown in Figure 3. 
 
The first pattern was elevated HCV viral loads despite the development of antibody responses. 
P8 and P13 (Figure 3a) were followed for 637 and 597 weeks, respectively, with two treatment 
interruptions triggering a rebound in HIV viremia and a decrease in CD4+ T-cell count. JFH-1 
antibody levels increased within the first year of ART and declined when ART was interrupted. 
HCV viral loads increased after weeks 144 and 22 (P8 and P13, respectively) and remained 
elevated. The rise was accompanied by an increase in nAb50 titres. Similar antibody profiles were 
seen for patients P4, P5, P9, P14 and P16 (data not shown).  
 
The second pattern was an inverse relationship between antibody responses and HCV viral loads 
which was seen for patients P1, P3, P6, P7, P10, P12, P15 and P17. For example; P12 (Figure 




interruptions. Levels of antibody reactive to JFH-1 and nAb50 titres were low at the start of ART 
but increased during follow-up, correlating with control of HCV viral replication. A rebound in 
HIV viremia at week 278 for P12 was associated with decreased CD4+ T-cell count, reduced 
JFH-1 antibody response and increased HCV viral load. For P7 (Figure 3b), a decline in 
antibody responses after 368 weeks was associated with a rise in HCV viral load. With the 
exception of P6, all patients who displayed an inverse relationship between nAb50 titres and 
HCV viral loads started ART with <100 CD4+ T-cells/l and experienced significant immune 
recovery (p<0.05 at 26, 104, 156 and 260 weeks).  
 
A mixed pattern was demonstrated in P2 who started ART with <50 CD4+ T-cell counts/L and 
achieved an immunological and virological response to ART (Figure 3c). JFH-1 antibody levels 
and nAb50 titres were low at week 4, but increased at 104 weeks with a concomitant rise in HCV 
viral load. Suppression of viral replication at week 152 paralleled a reduction in JFH-1 antibody 
and a HCV viral rebound at week 256 corresponded with an increase in JFH-1 antibody and 
nAb50 titres. However, failure to maintain nAb responses after 474 weeks was linked to a 
dramatic rise in HCV RNA levels, so the antibody profile changed from pattern 1 to pattern 2.   
 
3.7 Antibodies to JFH-1 declined on HCV therapy but antibodies to non-structural proteins 
increased with control of HCV replication 
Four patients received anti-HCV therapy. P1, P10 and P14 were treated with IFNα/ribavirin for 
48 weeks and achieved a sustained virological response, followed by lower JFH-1 antibody and 
nAb50 titres (Figures 4a,b & c). HCV core antibody levels also declined in patients with 
sustained virological response (data not shown). It is noteworthy that P10 was able to control 




the fact that this patient was infected with the genotype 2 strain of HCV which is the same as the 
JFH-1 strain used to assess neutralisation capacity. P4 was treated with IFNα alone for 20 weeks 
without a virological response and retained high JFH-1 reactive antibody levels and nAb50 titres 
(Figure 4d). As residual IFNα or ribavirin in the plasma may create false positives in the nAb 
assay, IgG was purified from P1, P10 and P14 plasmas collected before and after 
IFN/ribavirin. All nAb50 titres were comparable in purified IgG and the original samples 
(Supplementary Figure 4). 
 
Antibodies to HCV non-structural proteins (NS3, NS4, NS5) rose with control of HCV 
replication on ART in several patients (notably P2, P3, P5, P7, P10, P11, P15; Figure 5 and P9 
and P13 (not shown)). 
 
4. Discussion 
We present a comprehensive analysis of HCV-specific antibody responses in HIV/HCV co-
infected patients followed for 11 years after initiating ART. We used antigens from cell cultures 
infected with the HCV genotype 2a virus, JFH-1, and commercially available recombinant 
proteins from HCV genotype 1. An advantage of using JFH-1 is the inclusion of envelope 
proteins (E1 or E2). We show that patterns of antibody responses differ with the antigen.  Levels 
of JFH-1 and HCV core reactive antibodies were lower in untreated HIV/HCV patients than in 
HCV mono-infected patients. In contrast, levels of NS3 and NS5 antibody were high and NS4 
antibodies were similar to HCV mono-infected patients.  
 
Core is highly immunogenic, being recognized by 97% of patients with chronic HCV infection 




E2, NS3, NS4 and NS5 [21]. Thus the lower JFH-1 antibody levels observed in HIV/HCV 
patients may reflect reduced levels of antibody to core, despite the high antibody levels to NS3 
and NS5. Our findings differ from a report of weak reactivity to NS3, NS4 and NS5 antigens in 
HIV/HCV patients [22]. Increased NS3 and NS5 antibody levels could reflect the higher HCV 
viremia [23] expected in co-infected patients [24], though this was not evident here (Figure 5). 
 
Total IgG was assessed to evaluate non-specific activation of B-cells. Levels were elevated 
before ART and did not normalise, suggesting continued B-cell activation by HIV and/or HCV 
disease. This fits with evidence that HIV/HCV co-infected patients treated for 1 year retained 
elevated IgG [25]. Similarly, HIV mono-infected patients but not HCV/HIV patients normalised 
their total IgG levels after 3 years on ART [9].  In contrast to several studies [26, 27], IgG levels 
in HCV mono-infected patients were not higher than healthy controls (data not shown). This may 
reflect their mild fibrosis (13/17 patients had fibrosis scores of 1 or 2), as serum IgG levels may 
correlate with the severity of hepatic fibrosis in HCV-infected patients [28]. 
 
The generation of nAb plays an important role in host immunity. In acutely HCV-infected 
patients, nAb contribute to the control of HCV replication and eventual eradication of the virus 
[29, 30]. However in chronically-infected humans and chimpanzees [31] and in HIV/HCV 
patients with controlled HIV viremia [13], nAb50 titres did not correlate with HCV RNA levels. 
Here, genotype cross-reactive nAb50 titres were lower in untreated co-infected patients compared 
to HCV mono-infected patients, with undetectable or low titres of nAb in nine co-infected 





Baseline JFH-1 antibody levels correlated with CD4+ T-cell counts in HIV/HCV patients. 
Accordingly, antibodies to HCV core, NS3, NS4 and NS5 antigens were lowest in untreated 
HIV/HCV patients with CD4+ T-cell counts below 200 cells/L [32]. Here, antibody responses 
increased on ART, but only nAb50 titres reached levels seen in HCV mono-infected patients. We 
also demonstrated a significant increase in JFH-1 antibody levels and nAb50 titres in longitudinal 
samples from Indonesian HIV/HCV patients after 1 year of ART [18]. In a cross-sectional study 
of HIV/HCV patients who had controlled HIV viremia during ART, nAb50 titres were 
significantly lower than HCV mono-infected patients [13], but the duration of treatment was not 
specified. Here, nAb50 titres were significantly lower than HCV mono-infected patients during 
the first 4 years but normalised with longer periods of ART (Figure 2).  
 
Recovery of antibody responses on ART was also evident with CMV, and may reflect restored 
T-cell help for B-cell responses as it paralleled improved HCV-specific CD4+ and CD8+ T-cell 
responses [3, 4]. This trend over time was evident in our study, but increases in JFH-1 antibody 
responses on ART were independent of CD4+ T-cell counts at recruitment. In contrast, cell-
mediated T-cell responses to HCV antigens assessed by lymphoproliferation and interferon- 
ELISPOT were associated with nadir CD4+ T-cells counts [33, 34]. Interestingly, patients who 
started ART with low CD4+ T-cell counts developed nAb responses more rapidly than patients 
with high CD4+ T-cell counts and displayed an inverse correlation between nAb50 titres and 
HCV viral loads. Whilst this appears counterintuitive, virus-specific protective antibody 
responses were improved by partial CD4+ T-cell depletion or peptide tolerisation of virus-
specific CD4+ T-cells in murine lymphocytic choriomeningitis virus infection [35, 36]. The 
authors postulated that T-cell dependent polyclonal activation of B-cells reduced activation of 




failed to control HCV viral replication. In these individuals, virus-specific CD8+ T-cell 
responses may have a role in controlling viremia [37]. 
 
Liver enzyme levels increase in some HIV/HCV co-infected patients beginning ART [5-8]. This 
has been attributed to particular antiretroviral drugs or restoration of HCV-specific immune 
responses. Patients with elevated serum ALT levels can display high levels of HCV core 
antibody [8] and/or HCV antibodies assessed by diagnostic kits [7]. In the current study, 
antibody responses increased irrespective of changes in serum ALT during ART. Furthermore, 
median levels of antibody reactive with JFH-1 were similar in individuals with or without 
elevated ALT. However, we did not assess antibody responses between baseline and 26 weeks 
where most differences occur [7]. Similarly, JFH-1 reactive antibody levels were significantly 
raised in Indonesian patients with liver enzyme elevations at baseline and during the first 12 
weeks of ART but not at 24 and 48 weeks [18]. Further work is required to elucidate if HCV-
specific antibodies play a direct role in hepatotoxicity. 
 
Suppression of HCV replication by anti-HCV therapy was associated with reduced nAb50 titres, 
and antibodies to JFH-1, core and non-structural antigens (Figure 4). This suggests that the 
presence of antigen may boost production of antibodies. This association has been reported for 
several viruses including HCV [38] and HIV [39] and is the general basis for immunisation. For 
HIV/HCV patients treated with pegylated IFNα and ribavirin, sustained virological responses 
paralleled reductions in antibodies to HCV core and NS4 [40]. Accordingly, HCV mono-infected 
patients who resolved HCV infection without therapy had lower levels of antibodies to NS3 and 
NS5 than individuals with persistent viremia [23]. Furthermore, in patients with chronic HCV 




and NS5 declined for up to 10-years follow-up [41, 42]. A decline in antibody levels with HCV 
therapy seen here contradicts two studies in which clearance of HCV RNA following pegylated 
IFNα and ribavirin therapy did not change nAb50 titres to JFH-1 [43] or HCV pseudoparticles 
[44] in HCV mono-infected patients. This could reflect the short follow-up periods (<12 
months). We suggest that antibody responses to JFH-1 and/or recombinant antigens may help in 
assessing outcome of HCV therapy. It is important to note that antibodies to NS3, NS4 and NS5 
rose following clearance of HCV RNA on ART (Figure 5), presumably by immunological 
mechanisms. 
 
Limitations of this study include the small sample size and the heterogeneity of treatment 
regimes. Second, the use of plasma or serum in our neutralisation assay may be confounded by 
the presence of soluble factors that can affect virus infectivity in cell culture. However, we 
demonstrated strong positive correlations for nAb50 titres when plasma or purified IgG from 51 
HCV mono-infected patients was used for the assay (r=0.85, p<0.0001, unpublished data). Third, 
the neutralisation assay utilised a HCV genotype 2a virus strain, whilst most patients were 
infected with genotype 1 or 3. This may result in the underestimation of nAb50 titres. However, 
in 99 chronically HCV mono-infected patients [genotype 1 (n=47); genotype 2 (n=19), genotype 
3 (n=31); genotype 4 (n=2)], nAb50 titres were independent of HCV genotype (unpublished 
data). Nevertheless, there is a need for additional work using pseudoparticles encoding 
autologous E1-E2 sequences to confirm the undetectable or low nAb responses reported in 
several HIV/HCV patients. Fourth, we cannot conclude that a reduction in HCV viral loads was 
a direct consequence of increased nAb50 titres, as there may be concomitant generation of HCV-
specific CD4+ and CD8+ T-cell responses. It is well established that the presence of vigorous and 




clearance in acutely infected humans and chimpanzees [45, 46] and sustained virological 
responses in chronically infected patients receiving IFN and ribavirin combination therapy [47, 
48]. Further studies monitoring both humoral and cell-mediated immune responses at regular 
intervals in individual patients are warranted. However, considering these limitations, these 
longitudinal results builds a picture of how HCV antibody responses change during long-term 
ART in patients co-infected with HIV and HCV.  
 
In summary, antibody responses measured using the JFH-1 virus increase with long-term ART 
irrespective of baseline CD4+ T-cell counts. nAb responses correlate with control of HCV 
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Figure 1. Levels of circulating total IgG (a), CMV antibody (b) and antibodies to JFH-1 (c), 
HCV core (d), NS3 (e), NS4 (f), NS5 (g) and HCV nAb50 titres (h) in HIV/HCV co-infected 
patients, HCV mono-infected patients and healthy controls. JFH-1 antibody levels were 
determined by subtracting the value obtained with uninfected cells from the value for JFH-1 
lysate and averaged over several sample dilutions. The 50% neutralising antibody (nAb50) titre 
was the plasma dilution required to inhibit JFH-1 infection by 50%. Lines represent median 
values. p-values were determined using Mann Whitney T-Tests. 
 
Figure 2.  Levels of total IgG (a), CMV antibody (b), JFH-1 antibody (c) and nAb50 titres 
(d) in longitudinal samples from 17 HIV/HCV co-infected patients initiating ART. 
Longitudinal data were grouped to the nearest timepoint. The black lines represent the median 
values for HIV/HCV co-infected patients (a-d). The grey dotted lines represent the median 
values for healthy controls (a and b) or HCV mono-infected patients (c and d) and the shaded 
areas represent the 25th and 75th percentile. JFH-1 antibody levels were determined by 
subtracting the value obtained with uninfected cells from the value for JFH-1 lysate and averaged 
over several sample dilutions. The 50% neutralising antibody (nAb50) titre was the plasma 
dilution required to inhibit JFH-1 infection by 50%. 
 
Figure 3. Immunological, virological and biochemical details (top panel) and JFH-1 specific 
antibody responses (bottom panel) in longitudinal samples from HIV/HCV co-infected 
patients on ART. For the top panel, the darker grey shaded areas represent the HCV viral 
loads, the open circle line graph show the serum ALT levels and the closed diamond line graph 
represent the CD4+ T-cell counts. For the bottom panel, the open circle line graph represent 




is represented by grey shaded areas. HIV viral loads were considered detectable (+) if above 3.0 
log10 copies/mL. JFH-1 antibody levels were as described in Figure 3. The 50% neutralising 
antibody (nAb50) titre was the plasma dilution required to inhibit JFH-1 infection by 50%. 
 
Figure 4. Immunological, virological and biochemical details (left panel) and JFH-1 specific 
antibody responses (right panel) in longitudinal samples from HIV/HCV co-infected 
patients who achieved a sustained virological response (a-c) or did not respond following 
IFNα-based therapy (d). For the left panel, the darker grey shaded areas represent the HCV 
viral loads, the open circle line graph show the serum ALT levels and the closed diamond line 
graph represent the CD4+ T-cell counts. For the right panel, the open circle line graph represent 
nAb50 titres and the closed circle line graph show the JFH-1-reactive antibody levels. Time on 
ART or IFNα-based therapy are represented by grey shaded areas or hatched bars respectively. 
HIV viral loads were considered detectable (+) if above 3.0 log10 copies/mL. JFH-1 antibody 
levels were as described in Figure 3. The 50% neutralising antibody (nAb50) titre was the plasma 
dilution required to inhibit JFH-1 infection by 50%. 
 
Figure 5. Antibody levels to recombinant HCV antigens in longitudinal samples from 7 
HIV/HCV co-infected patients on ART. The closed circle line graph represent antibody levels 
to HCV core, the open circle line graph show antibody levels to HCV NS3, the closed diamond 
line graph represent antibody levels to HCV NS4 and the open diamond line graph show 
antibody levels to HCV NS5. Time on ART or IFNα-based therapy are represented by light grey 
shaded areas or hatched bars respectively. HIV viral loads were considered detectable (+) if 




levels were as described in Figure 3. The 50% neutralising antibody (nAb50) titre was the plasma 
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Table 1. Characteristics of HIV/HCV co-infected patients 
Patient 
ID 



















therapy First Last 
P1 35 M W 1 -18 660 40 552 58 5.45 8331 NRa, SVRb 
P2 43 M W 1 0 609 48 220 71 5.88 3572 NT 
P3 33 M W 1 0 598 112 322 51 4.75 20223 NT 
P4 43 M W 1 -15 720 260 793 33 3.68 59238 NRa 
P5 28 M AS 1 -11 515 150 825 86 3.01 1903 NT 
P6 30 M W 1 -17 478 405 795 22 4.50 < 200 NT 
P7 37 M W 1 -2 599 30 750 15 5.48 < 200 NT 
P8 32 F W 1 0 637 425 952 42 4.16 26051 NT 
P9 37 M AS 3 0 465 266 1273 28 4.02 < 200 NRa 
P10 34 M AS 2 0 574 40 490 38 5.33 11062454 SVRb 
P11 37 M W 3 -13 766 20 168 40 5.58 < 200 NT 
P12 36 M W ND -7 452 44 869 ND 6.60 40920 NT 
P13 40 M W 1 -2 597 360 774 76 5.02 < 200 NT 
P14 34 F W 1 -4 718 429 341 35 4.36 319984 SVRb 
P15 32 M W 1 -9 528 65 910 34 4.62 126327 NT 
P16 30 M AB 1 -2 393 210 798 56 4.88 1546 NT 
P17 29 F W ND -36 186 64 1168 321 5.55 < 200 NT 
 
W: White, AS: Asian, AB: Aboriginal, ND: Not determined, SVR: Sustained Virological Response, NR: Non-responders, NT: Not treated 
Reference ranges for healthy individuals: CD4+ T-cell count (457 – 1498) and CD8+ T-cell count (205 – 1013)  
* At study entry, # log10 copies/mL, ^ copies/mL, a IFNα monotherapy, b IFNα and ribavirin combination therapy, 1 19 weeks follow-up, 2 4 weeks follow-up, 3 9 weeks 
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Supplementary Figure 1. CD4+ T-cells counts (a) and serum ALT levels (b) in longitudinal 
samples from HIV/HCV co-infected patients on ART. Longitudinal data were grouped to the 
nearest time-point. Data are presented as box and whisker plots where the lower and upper limits 
of the central box represent the 25th and 75th percentile. The middle line represents the median.  
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Supplementary Figure 2.  Antibody levels to HCV core (a), NS3 (b), NS4 (c) and NS5 (d) in longitudinal samples for 17 HIV/HCV co-
infected patients on ART. Longitudinal data were grouped to the nearest time-point. The black lines represent the median values for 
HIV/HCV co-infected patients (a-d). The grey dotted lines represent the median values for HCV mono-infected patients and the shaded areas 
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Supplementary Figure 3.  Levels of JFH-1-reactive antibody (a) and nAb50 titres (b) in 
longitudinal samples from HIV/HCV co-infected patients stratified as having CD4+ T-cell counts 
of >50 (grey bars) (n=10) or <50 (white bars) (n=7) cells/L at study entry. Longitudinal data were 






upper limits of the central box represent the 25th and 75th percentile. The middle line represents the 
median. JFH-1 antibody levels were determined by subtracting the value obtained with uninfected cells 
from the value for JFH-1 lysate and averaged over several sample dilutions. The 50% neutralising 








































































































































































































Supplementary Figure 4. Neutralisation curves for plasma and purified IgG from 3 HIV/HCV co-
infected patients (P1, P10 and P14). Capacity for neutralisation was compared between plasma (left) 
and IgG purified using Protein G (right). Two samples were collected during IFN/ribavirin therapy 
































Age (years) 34 (28 – 43) 39 (29 – 49) 57 (30 – 74) 0.003 
Sex (M / F) 14 / 3 14 / 3  15 / 2  
ALT (U/mL) 41 (15 – 321) 69 (21 – 314) ND 0.013 
CD4+ T-cell count 150 (20 – 429) 938 (637 – 2142) ND <0.0001 
CD8+ T-cell count 793 (168 – 1273) 597 (273 – 1428) ND 0.552 
HCV genotype  
        1 / 2 / 3 / ND 
 
11 / 1 / 3 / 2 
 
11 / 1 / 3/ 2 
  
 
Results are present as median (range). p-values were determined using Mann Whitney T Test. ND, Not determined 
*HIV/HCV vs HCV 
 
